Dr. Richard Porter joined uniQure as General Manager of the Corlieve subsidiary following the acquisition of Corlieve in July 2021. He is responsible for progressing and building the portfolio in the Corlieve subsidiary.
Dr. Porter was the founder and CEO of Corlieve. He brings more than 25 years of R&D experience to uniQure, having previously served as the COO of Therachon until its acquisition by Pfizer. Previously he was at Roche in positions of increasing responsibility, most recently as the Global Head of Scientific Business Strategy and Operations for Neuroscience Ophthalmology and Rare Diseases directing the strategic and operational activities of the department. He has also served as a Product General Manager of the Emerging Business Unit at Shire Pharmaceuticals and has held scientific leadership positions at Vernalis and ASTRA.
Richard earned his Ph.D. in neuropharmacology from Southampton University (UK) and conducted his postdoctoral training at the Strong Memorial Hospital, University of Rochester, NY (USA) and the University of Oxford (UK).